Skip to content

Effect of Dexmedetomidine Hydrochloride Nasal Spray on Postoperative Delirium in Elderly Patients: A Multicenter, Randomized Controlled Trial

Effect of Dexmedetomidine Hydrochloride Nasal Spray on Postoperative Delirium in Elderly Patients: A Multicenter, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109274
Enrollment
Unknown
Registered
2025-09-16
Start date
2025-10-10
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative delirium (POD)

Interventions

Control group:An equal volume of sterile 0.9% NaCl was administered intranasally before surgery
Dexmedetomidine Hydrochloride Nasal Spray Group:Dexmedetomidine Hydrochloride nasal spray was administered preoperatively
Exploring the effective dose groups(Part 1):Dexmedetomidine nasal spray

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 65 years and above; 2. Planning to undergo non-cardiac surgery under general anesthesia; 3. ASA classification I to III; 4. Estimated surgery time greater than 1 hour; 5. Expected postoperative hospital stay of 2 days or more.

Exclusion criteria

Exclusion criteria: 1.Patients diagnosed with delirium preoperatively using the 3D-CAM scale; 2.Cognitive impairment was defined by education-stratified MMSE cutoffs: =IV; 6.Cardiac or cranial surgery; 7.Sick sinus syndrome, clinically significant sinus bradycardia, or second-degree or higher heart block without a pacemaker; 8.Severe hepatic insufficiency (Child-Pugh class C); 9.Patients requiring preoperative dialysis; 10.Allergy to a2-adrenergic agonists; 11.History of nasal conditions, surgeries, or allergies judged by the investigator to be clinically significant and severely affecting drug absorption (e.g., chronic nasal congestion, rhinorrhea, epistaxis; structural nasal abnormalities or mucosal lesions impairing absorption); 12.Emergency surgery; 13.Any other condition deemed by the investigator to render the patient unsuitable for the trial (e.g., inability to maintain the required position for dexmedetomidine nasal spray administration: sitting or semi-recumbent); 14.Enrollment in other clinical trials during the screening period.

Design outcomes

Primary

MeasureTime frame
Postoperative delirium (POD) incidence;Number of intranasal sprays of dexmedetomidine hydrochloride (Part 1).;Positive or negative reaction(Part1);

Secondary

MeasureTime frame
Intraoperative anesthetic consumption, and postoperative pain outcomes";Preoperative anxiety and stress levels;Postoperative recovery profile;ICU admission rates;Major Complications Within 30 Days Postoperatively;Postoperative pain profile;Vital signs;Subjective sleep quality;Postoperative Hospital Stay Duration;Operative Duration;Vital signs (Part1);Time to first achieve a Ramsay Sedation Score >= 3 (Part 1).;Adverse events(Part1);

Countries

China

Contacts

Public ContactLuo Foquan

Zhejiang Provincial People's Hospital

lfqjxmc@126.com+86 571 85893300

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026